← Back to Clinical Trials
Recruiting NCT04770519

NCT04770519 Genetic Studies of Strabismus, Nystagmus, and Associated Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04770519
Status Recruiting
Phase
Sponsor Boston Children's Hospital
Condition Strabismus
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2021-09-03
Primary Completion 2030-12

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
whole genome sequencing or whole exome sequencing

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2021-09-03 with a primary completion date of 2030-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Strabismus (misalignment of the eyes) often runs in families. In this study, the investigators are looking for genetic variants associated with strabismus and nystagmus. Three types of subects will be enrolled: (1) Families with at least 3 members with strabismus, (2) individuals with infantile esotropia and their parents and siblings, and (3) individuals with infantile nystagmus and their parents. Whole exome and/or whole genome sequencing will be used to identify genetic variants shared by family members with strabismus and to identify genetic causes of nystagmus.

Eligibility Criteria

Inclusion Criteria: \- Member of a family with at least 3 biological relatives with strabismus. (Both affected and non-affected family members will be enrolled). OR \- Member of a family with at least 1 individual with infantile esotropia. (Both affected and non-affected family members will be enrolled). OR \- Member of a family with at least 1 individual with infantile nystagmus. (Both affected and non-affected family members will be enrolled). Exclusion Criteria: * paralytic strabismus in affected family members

Contact & Investigator

Central Contact

Kayleen Cremin, BA

✉ research.whitman@childrens.harvard.edu

📞 857-292-3768

Principal Investigator

Mary Whitman, MD/PhD

PRINCIPAL INVESTIGATOR

Assistant Professor

Frequently Asked Questions

Who can join the NCT04770519 clinical trial?

This trial is open to participants of all sexes, studying Strabismus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04770519 currently recruiting?

Yes, NCT04770519 is actively recruiting participants. Contact the research team at research.whitman@childrens.harvard.edu for enrollment information.

Where is the NCT04770519 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT04770519 clinical trial?

NCT04770519 is sponsored by Boston Children's Hospital. The principal investigator is Mary Whitman, MD/PhD at Assistant Professor. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology